@article {Su2020.06.23.20136200, author = {Qiang Su and Jie-xuan Hu and Hai-shan Lin and Zheng Zhang and Emily C. Zhu and Chen-guang Zhang and Di-ya Wang and Zu-hua Gao and Bang-wei Cao}, title = {Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis}, elocation-id = {2020.06.23.20136200}, year = {2020}, doi = {10.1101/2020.06.23.20136200}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background The corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events.Methods We searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies{\textquoteright} risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.Findings Out of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97\% (95\% CI, 3.08\% to 5.12\%), higher than that of the total cancer rate (0.29\%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59\% (95\% CI, 1.72\% to 3.90\%), and the prevalence reached 3.79\% in Wuhan (95\% CI, 2.51\% to 5.70\%) and 2.31\% (95\% CI, 1.16\% to 4.57\%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80\% (95\% CI, 21.65\% to 32.67\%) and the mortality was 24.32\% (95\% CI, 13.95\% to 38.91\%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95\% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95\% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95\% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95\% CI, 0.47 to 1.33; p=0.45).Interpretation This comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients. Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.Funding Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ202010025047).Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding Beijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ202010025047).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval or patient consent was not required because the present study was a review of previously published articles.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used to support the findings of this study are available from the corresponding author upon request. https://figshare.com/s/8d089dc9c69f2dc483f5}, URL = {https://www.medrxiv.org/content/early/2020/06/24/2020.06.23.20136200}, eprint = {https://www.medrxiv.org/content/early/2020/06/24/2020.06.23.20136200.full.pdf}, journal = {medRxiv} }